Cleavage of TrGSDME by caspases.

(A, B) TrGSDME was treated with different HsCASPs and then subjected to SDS-PAGE (A) and immunoblotting (B). (C) SDS-PAGE analysis of purified TrCASP3/7. The p10 and p20 subunits are indicated. (D) TrCASP3/7 cleavage of different colorimetric CASP substrates was monitored by measuring released ρNA. The values are the means ± SD of three replicates. (E) TrCASP3/7 (0.25-8U) were incubated with Ac-DEVD-ρNA, and time-dependent release of ρNA was measured. (F, G) SDS-PAGE (F) and immunoblotting (G) analysis of TrGSDME cleavage by TrCASP3/7 (0.25-4U). (H) TrGSDME cleavage by TrCASP3/7 was determined in the presence or absence of Z-DEVD-FMK or Z-VAD-FMK. (I, J) TrGSDME wild type (WT) and mutants (D255R or D258A) were incubated with TrCASP3/7, and the cleavage was determined by SDS-PAGE (I) and immunoblotting (J). (K) A schematic of TrGSDME cleavage by TrCASP3/7. The arrow indicates cleavage site. For all panels, FL, full length; NT, N-terminal fragment; CT, C-terminal fragment.

The pyroptotic activity of TrGSDME.

(A-C) HEK293T cells expressing mCherry-tagged TrGSDME full length (FL) or truncates (NT or CT) were analyzed for TrGSDME expression (A), morphological change (B) and LDH release (C). Scale bars, 50 μm (A) and 20 μm (B). (D) HKE293T cells were transfected with the backbone vector or vector expressing Myc-tagged TrGSDME-NT. The cell nuclei and membrane were stained with PI and DiO, respectively. Scale bar, 10 μm. (E) HEK293T cells were transfected with mCherry-tagged TrGSDME-NT, and the progression of cell death was shown by time-lapse microscopic imaging. Scale bar, 10 μm. (F) HEK293T cells were transfected with TrCASP3/7, and the proteolytic activity of TrCASP3/7 was assessed by treatment with fluorogenic Ac-DEVD-AFC. (G) Phase-contrast images of HEK293T cells transfected with the indicated vectors. Scale bar, 20 μm. (H, I) LDH release (H) and TrGSDME cleavage (I) in the above transfected cells were determined. For panel (I), FL, full-length; CT, C-terminal fragment. (J, K) HKE293T cells co-expressing TrGSDME and TrCASP3/7 in the presence or absence (control) of Z-VAD-FMK or Z-DEVD-FMK were subjected to microscopy (J) and LDH measurement (K). Scale bar, 20 μm. (L, M) HEK293T cells expressing TrCASP3/7 plus TrGSDME or TrCASP3/7 plus the D255R/D258A mutant were subjected to microscopy (L) and LDH measurement (M). Scale bar, 20 μm. For panels (C, F, H, K and M), values are the means of three experimental replicates and shown as means ±SD. **P < 0.01, ***P < 0.001.

GSDME-CT domain determines the recognition by CASP7.

(A) HsGSDME was treated with various HsCASPs, and the products were analyzed by immunoblotting with anti-HsGSDME-CT antibody. (B) HsCASP3/7 and TrCASP3/7 were incubated with Ac-DAVD-ρNA or Ac-DMPD-ρNA, and the proteolytic activity was determined. Data are expressed as the means ±SD of three replicates. (C) Sequence alignment of the linker region from HsGSDME and TrGSDME. Two regions that may form α-helix and β-strand are indicated. (D) HsGSDME wild type (WT) and mutants (Δ261-266 and Δ281-296) were treated with or without HsCASP3/7, and the cleaved fragments were subjected to immunoblotting with anti-HsGSDME-CT antibody. (E) Schematics of the chimeric GSDME constructs. (F-I) TrGSDME (F), HsNT-TrCT (G), HsGSDME (H) and TrNT-HsCT (I) were incubated with TrCASP3/7 or HsCASP3/7, and the cleavage was determined by immunoblotting with anti-TrGSDME or anti-HsGSDME-CT antibodies. For panels (A, D, and F-I): FL, full length; NT, N-terminal fragment; CT, C-terminal fragment.

The p10 subunit of CASP7 is essential for discrimination on GSDME.

(A) Sequence alignment of HsCASP7 and TrCASP7. α-helices and β-strands are indicated. The motifs involved in catalytic reaction (SHG and QACRG) and substrate binding (SWR and GSWF) are boxed in red. (B) Schematics of CASP7 chimeras. (C) The proteolytic activities of TrCASP7, HsCASP7 and their chimeras were determined by cleaving Ac-DAVD-ρNA and Ac-DMPD-ρNA. Data are expressed as the means ± SD of three replicates. (D-G) TrGSDME (D), HsNT-TrCT (E), HsGSDME (F) or TrNT-HsCT (G) were incubated with TrCASP7, HsCASP7 and their chimeras. The products were assessed by immunoblotting with anti-TrGSDME or anti-HsGSDME-CT antibodies. For panels (D-G): FL, full length; NT, N-terminal fragment; CT, C-terminal fragment.

Functional importance of the non-conserved residues in the p10 of HsCASP7 and TrCASP7.

(A) Sequence alignment of the p10 region in HsCASP7 and TrCASP7. The arrows indicate non-conserved residues. (B, C) HsGSDME was treated with wild type (WT) or mutant HsCASP7 (B) or TrCASP7 (C). The cleavage was determined by immunoblotting with anti-HsGSDME-CT antibody. 205TME, HsCASP7 with TME insertion at position 205; 213ΔTME, TrCASP7 with TME deleted at position 213. (D, E) TrGSDME was incubated with wild type (WT) or mutant HsCASP7 (D) or TrCASP7 (E). The cleavage was determined by immunoblotting with anti-TrGSDME antibody. (F) HsGSDME was incubated with HsCASP7 or the S234N mutant (0.25-4U). HsGSDME cleavage was analyzed as above. (G, H) HsGSDME (G) and TrGSDME (H) were treated with wild type or mutant HsCASP7. The cleavage was determined as above. (I, J) TrGSDME (I) or HsGSDME (J) was co-expressed with different doses of TrCASP7/HsCASP7 in HEK293T cells. GSDME cleavage, CASP7 and β-actin were determined by immunoblotting. (K, L) TrGSDME (K) or HsGSDME (L) was co-expressed with wild type or mutant TrCASP7/HsCASP7. GSDME cleavage, CASP7 and β-actin were determined as above. (M) HsGSDME was co-expressed with HsCASP7 or HsCASP7-S234N. Cleavage of GSDME was detected as above. For panels (B-M): FL, full length; NT, N-terminal fragment; CT, C-terminal fragment.

Conservation and functional importance of S/N234 in CASP3/7.

(A) Weblogo analysis of the conservation of S/N234 in CASP3/7 in Mammalia, Aves, Reptilia, Amphibia and Osteichthyes. (B) Sequence alignment of HsCASP3/7. The S/N residues are indicated by red arrow. (C) HsGSDME was treated with HsCASP3 or HsCASP3-N208S, and then subjected to immunoblotting with anti-HsGSDME-CT antibody. (D) HsGSDME was co-expressed in HEK293T cells with different doses of HsCASP3 or HsCASP3-N208S. The cell lysates were immunoblotted to detect HsGSDME, CASP3, and β-actin. (E) Sequence alignment of the S/N234 region in the CASP7 of primate (shaded cyan) and non-primate mammals. The S/N residues are indicated by red arrow. Asterisks indicate identical residues. (F) Alignment of human and mouse CASP7 sequences. The S/N234 residues are indicated by arrow. (G) HsGSDME was treated with different units of HsCASP7 or MmCASP7, and the cleavage was assessed by immunoblotting with anti-HsGSDME-CT antibody. (H) HsGSDME was incubated with different units of MmCASP7 or its mutant (N234S), and HsGSMDE cleavage was analyzed as above. (I) MmCASP7 was treated with HsCASP7, MmCASP7 or MmCASP7-N234S. The cleavage was determined by immunoblotting with anti-MmGSDME-NT antibody. For panels (C, D, and G-I), FL, full length; NT, N-terminal fragment; CT, C-terminal fragment.

The credits for the pictures used in this study. Icons Figure Origin

Primers used in this study.

Preparation of recombinant proteins.

(A) SDS-PAGE analysis of purified Hsp20-Trp10 and Trp20-Hsp10. (B, C) Recombinant mutants of TrCASP7 (B) and HsCASP7 (C) were purified and subjected to SDS-PAGE. (D) HsCASP3 and its mutant (N208S) were analyzed by SDS-PAGE. (E) SDS-PAGE analysis of purified MmCASP7 and its mutant (N234S). In all panels, the p10 and p20 subunits are indicated.

Conservation of S/N234 in mammalian CASP7.

The four conserved amino acids are shown in LOGOs, with height representing the relative proportion of the corresponding amino acid at that position. The S/N234 is presented as the fourth LOGO and indicated with a red star.